Drug Delivery - Pembrolizumab For Car-Net-1 Clinical Trial. The Subject Of The Agreement Is The Successive Delivery Of Investigational Medicinal Products (Hereinafter Referred To As Bpl Or Imp) Containing The Active Substance Pembrolizumab For The Purposes Of The Non-Commercial Clinical Trial Multicenter, Open-Label Phase I/Ii Study To Assess The Feasibility, Safety And Effectiveness Of Treatment With Anti-Cd19 Car T Cells Produced From Lymphocytes Obtained By Pre-Emptive Leukapheresis In Patients With Aggressive B-Cell Lymphomas And Acute Lymphoblastic Leukemia (All) After Failing Second-Line Treatment, Followed By Short-Term Treatment With Pembrolizumab , Protocol Number: Carnet1 (Hereinafter: Clinical Trial Or Carnet1 Study). A Detailed Description Of The Subject Of The Order Is Specified In Appendix 2 To The Tor And In The Draft Agreement Constituting Appendix 6.
We takes all possible care for accurate & authentic tender information, however Users are requested to refer Original source of Tender Notice / Tender Document published by Tender Issuing Agency before taking any call regarding this tender.
